Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors - Fierce Pharma
During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive momentum highlighted by the
Comments